JP2021098733A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021098733A5 JP2021098733A5 JP2021037490A JP2021037490A JP2021098733A5 JP 2021098733 A5 JP2021098733 A5 JP 2021098733A5 JP 2021037490 A JP2021037490 A JP 2021037490A JP 2021037490 A JP2021037490 A JP 2021037490A JP 2021098733 A5 JP2021098733 A5 JP 2021098733A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 116
- 239000000427 antigen Substances 0.000 claims 53
- 102000036639 antigens Human genes 0.000 claims 53
- 108091007433 antigens Proteins 0.000 claims 53
- 102000004169 proteins and genes Human genes 0.000 claims 36
- 108090000623 proteins and genes Proteins 0.000 claims 36
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 25
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 25
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 25
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 25
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 25
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 12
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 12
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 12
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 9
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 7
- 102100039496 Choline transporter-like protein 4 Human genes 0.000 claims 4
- 101710148283 Choline transporter-like protein 4 Proteins 0.000 claims 4
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 4
- 102100023123 Mucin-16 Human genes 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 claims 3
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- LJPIRKICOISLKN-WHFBIAKZSA-N Gly-Ala-Ser Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O LJPIRKICOISLKN-WHFBIAKZSA-N 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102100024364 Disintegrin and metalloproteinase domain-containing protein 8 Human genes 0.000 claims 1
- 101710116123 Disintegrin and metalloproteinase domain-containing protein 8 Proteins 0.000 claims 1
- 102100024361 Disintegrin and metalloproteinase domain-containing protein 9 Human genes 0.000 claims 1
- 101710116121 Disintegrin and metalloproteinase domain-containing protein 9 Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 102100038437 Sodium-dependent phosphate transport protein 2B Human genes 0.000 claims 1
- 108050003877 Sodium-dependent phosphate transport protein 2B Proteins 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- CFDVGUXRLQWLJX-QGTNPELVSA-N beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)C(O)O[C@@H]1CO CFDVGUXRLQWLJX-QGTNPELVSA-N 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 238000007596 consolidation process Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 150000002270 gangliosides Chemical class 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000001608 potassium adipate Substances 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000001601 sodium adipate Substances 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555110P | 2017-09-07 | 2017-09-07 | |
| US62/555,110 | 2017-09-07 | ||
| US201762566824P | 2017-10-02 | 2017-10-02 | |
| US62/566,824 | 2017-10-02 | ||
| JP2020513796A JP7431392B2 (ja) | 2017-09-07 | 2018-09-07 | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513796A Division JP7431392B2 (ja) | 2017-09-07 | 2018-09-07 | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021098733A JP2021098733A (ja) | 2021-07-01 |
| JP2021098733A5 true JP2021098733A5 (enExample) | 2021-10-14 |
Family
ID=65634405
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513796A Active JP7431392B2 (ja) | 2017-09-07 | 2018-09-07 | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 |
| JP2021037490A Pending JP2021098733A (ja) | 2017-09-07 | 2021-03-09 | Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質 |
| JP2023132099A Pending JP2023166409A (ja) | 2017-09-07 | 2023-08-14 | Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質 |
| JP2025026082A Pending JP2025093943A (ja) | 2017-09-07 | 2025-02-20 | Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513796A Active JP7431392B2 (ja) | 2017-09-07 | 2018-09-07 | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023132099A Pending JP2023166409A (ja) | 2017-09-07 | 2023-08-14 | Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質 |
| JP2025026082A Pending JP2025093943A (ja) | 2017-09-07 | 2025-02-20 | Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20200277383A1 (enExample) |
| EP (2) | EP3925976A1 (enExample) |
| JP (4) | JP7431392B2 (enExample) |
| KR (3) | KR20240167101A (enExample) |
| CN (3) | CN111315782A (enExample) |
| AU (3) | AU2018329937B2 (enExample) |
| BR (1) | BR112020004489A2 (enExample) |
| CA (2) | CA3112984A1 (enExample) |
| IL (2) | IL273067A (enExample) |
| MX (2) | MX420258B (enExample) |
| RU (1) | RU2021110369A (enExample) |
| SG (2) | SG11202001930QA (enExample) |
| WO (1) | WO2019051308A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX386014B (es) | 2016-08-10 | 2025-03-18 | Univ Ajou Ind Academic Coop Found | Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma. |
| CA3053010A1 (en) | 2017-02-08 | 2018-08-16 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CA3054079A1 (en) | 2017-02-20 | 2018-08-23 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| DK3749346T3 (da) | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| JP2021512914A (ja) | 2018-02-08 | 2021-05-20 | ドラゴンフライ セラピューティクス， インコーポレイテッド | ナチュラルキラー細胞を活性化する多特異的結合タンパク質を伴うがんの併用療法 |
| SG11202007945UA (en) | 2018-02-20 | 2020-09-29 | Dragonfly Therapeutics Inc | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| KR20250112921A (ko) | 2018-08-08 | 2025-07-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3870598A1 (en) | 2018-10-23 | 2021-09-01 | Dragonfly Therapeutics, Inc. | Heterodimeric fc-fused proteins |
| CN113677364B (zh) | 2018-12-03 | 2024-07-05 | 艾更斯司股份有限公司 | 包含抗191p4d12抗体药物偶联物的药物组合物及其使用方法 |
| JP2022553818A (ja) * | 2019-10-30 | 2022-12-26 | ザ テキサス エー アンド エム ユニバーシティ システム | 二重標的キメラ抗原レセプターｔ細胞療法のためのプロテアーゼスイッチ |
| MX2022013112A (es) * | 2020-04-22 | 2023-01-16 | Dragonfly Therapeutics Inc | Fórmulacion, regimen de dosificación y proceso de manufactura de proteínas heterodiméricas fusionadas con fc. |
| BR112022021884A2 (pt) | 2020-05-06 | 2022-12-20 | Dragonfly Therapeutics Inc | Proteínas que se ligam a nkg2d, cd16 e clec12a |
| AU2021344976A1 (en) * | 2020-09-17 | 2023-04-27 | Agensys, Inc. | Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
| CN117222663A (zh) | 2021-03-03 | 2023-12-12 | 蜻蜓疗法股份有限公司 | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 |
| CN113563474B (zh) * | 2021-06-11 | 2023-05-02 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | EpCAM-CD16-NKG2D三特异性抗体及其应用 |
| EP4388103A1 (en) * | 2021-08-20 | 2024-06-26 | Tallac Therapeutics, Inc. | Nectin-4 antibodies and conjugates |
| AU2022358500A1 (en) * | 2021-09-29 | 2024-04-04 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and baff-r |
| KR20230060546A (ko) * | 2021-10-22 | 2023-05-04 | 상트네어바이오사이언스 주식회사 | 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| AU2023316566A1 (en) * | 2022-07-25 | 2025-01-30 | Agensys, Inc. | Methods for treating patients with locally advanced or metastatic urothelial cancer with antibody drug conjugates (adc) that bind 191p4d12 proteins in combination with pembrolizumab |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6015301A (en) * | 2000-03-24 | 2001-10-03 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| JP2003111595A (ja) * | 2001-06-25 | 2003-04-15 | Kyogo Ito | 腫瘍抗原 |
| CN1812999A (zh) * | 2003-05-31 | 2006-08-02 | 麦克罗梅特股份公司 | 包含EpCAM特异构建体的药物组合物 |
| JP2009500346A (ja) | 2005-06-29 | 2009-01-08 | ユニバーシティー・オブ・マイアミ | 癌処置用の抗体−免疫細胞リガンド融合タンパク質 |
| NZ568551A (en) | 2005-12-08 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to Fucosyl-GM1 and methods using anti-Fucosyl-GM1 |
| US20110301056A1 (en) | 2008-12-12 | 2011-12-08 | Oncotherapy Science, Inc. | Nectin-4 for target genes of cancer therapy and diagnosis |
| EP2403524A4 (en) | 2009-03-06 | 2012-09-26 | Agensys Inc | CONJUGATES ANTIBODY-DRUG (ADC) BINDING PROTEINS 24P4C12 |
| GB0909904D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Product |
| CN102481367B (zh) * | 2009-07-06 | 2015-04-29 | 弗·哈夫曼-拉罗切有限公司 | 结合地高辛配基的双特异性抗体 |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| MX369679B (es) | 2010-09-29 | 2019-11-15 | Agensys Inc | Conjugados de anticuerpo fármaco (adc) que enlazan a proteínas 191p4d12. |
| JP6400470B2 (ja) * | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| CN112079929A (zh) | 2012-11-21 | 2020-12-15 | 武汉友芝友生物制药有限公司 | 双特异性抗体 |
| CA2900764A1 (en) * | 2013-02-08 | 2014-08-14 | Stemcentrx, Inc. | Novel multispecific constructs |
| MX384142B (es) * | 2013-07-16 | 2025-03-14 | Genentech Inc | Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer. |
| WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| EP3327038B1 (en) * | 2013-12-20 | 2020-09-23 | F. Hoffmann-La Roche AG | Bispecific her2 antibodies and methods of use |
| CA2934818C (en) | 2013-12-23 | 2022-05-17 | John Babcook | Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof |
| WO2016115274A1 (en) | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| CN107530424A (zh) | 2015-02-20 | 2018-01-02 | 俄亥俄州国家创新基金会 | 针对nkg2d和肿瘤相关抗原的二价抗体 |
| WO2017042210A1 (en) | 2015-09-09 | 2017-03-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
| CA3053010A1 (en) * | 2017-02-08 | 2018-08-16 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| DK3749346T3 (da) * | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| CN117222663A (zh) * | 2021-03-03 | 2023-12-12 | 蜻蜓疗法股份有限公司 | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 |
| US20230416402A1 (en) * | 2022-03-03 | 2023-12-28 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2 |
-
2018
- 2018-09-07 CN CN201880071464.8A patent/CN111315782A/zh active Pending
- 2018-09-07 JP JP2020513796A patent/JP7431392B2/ja active Active
- 2018-09-07 RU RU2021110369A patent/RU2021110369A/ru unknown
- 2018-09-07 MX MX2020002626A patent/MX420258B/es unknown
- 2018-09-07 WO PCT/US2018/050073 patent/WO2019051308A1/en not_active Ceased
- 2018-09-07 KR KR1020247038586A patent/KR20240167101A/ko active Pending
- 2018-09-07 EP EP21164073.5A patent/EP3925976A1/en not_active Withdrawn
- 2018-09-07 KR KR1020207009780A patent/KR20200044957A/ko not_active Ceased
- 2018-09-07 CA CA3112984A patent/CA3112984A1/en active Pending
- 2018-09-07 AU AU2018329937A patent/AU2018329937B2/en active Active
- 2018-09-07 SG SG11202001930QA patent/SG11202001930QA/en unknown
- 2018-09-07 SG SG10202102502VA patent/SG10202102502VA/en unknown
- 2018-09-07 CA CA3074840A patent/CA3074840A1/en active Pending
- 2018-09-07 EP EP18853095.0A patent/EP3679071A4/en active Pending
- 2018-09-07 KR KR1020217007213A patent/KR20210030503A/ko not_active Ceased
- 2018-09-07 BR BR112020004489-0A patent/BR112020004489A2/pt unknown
- 2018-09-07 CN CN202411838715.4A patent/CN119735693A/zh active Pending
- 2018-09-07 US US16/644,585 patent/US20200277383A1/en not_active Abandoned
- 2018-09-07 CN CN202110251101.6A patent/CN113004417A/zh active Pending
-
2020
- 2020-03-04 IL IL273067A patent/IL273067A/en unknown
- 2020-03-06 MX MX2021002970A patent/MX2021002970A/es unknown
-
2021
- 2021-03-02 US US17/190,155 patent/US20210292420A1/en not_active Abandoned
- 2021-03-08 IL IL281323A patent/IL281323A/en unknown
- 2021-03-09 AU AU2021201494A patent/AU2021201494A1/en not_active Abandoned
- 2021-03-09 JP JP2021037490A patent/JP2021098733A/ja active Pending
-
2023
- 2023-02-13 US US18/108,961 patent/US20230357409A1/en active Pending
- 2023-08-14 JP JP2023132099A patent/JP2023166409A/ja active Pending
-
2024
- 2024-12-11 AU AU2024278313A patent/AU2024278313A1/en active Pending
-
2025
- 2025-02-20 JP JP2025026082A patent/JP2025093943A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021098733A5 (enExample) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| RU2021110369A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2020508997A5 (enExample) | ||
| JP2021098732A5 (enExample) | ||
| Fischer et al. | Bispecific antibodies: molecules that enable novel therapeutic strategies | |
| FI3749346T3 (fi) | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät | |
| FI3582806T3 (fi) | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja | |
| JP2020521448A5 (enExample) | ||
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JP2021035388A5 (ja) | Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２またはクローディン−１８．２を標的にする多重特異性結合タンパク質 | |
| JP2023052214A5 (enExample) | ||
| CN115052893A (zh) | 抗tigit抗体和使用方法 | |
| JP2020522473A5 (enExample) | ||
| JP2023106433A5 (enExample) | ||
| Müller et al. | Bispecific antibodies | |
| JPWO2020033702A5 (enExample) | ||
| JP2020522474A5 (enExample) | ||
| JPWO2019157366A5 (enExample) | ||
| JPWO2020033587A5 (enExample) | ||
| CN116396386A (zh) | Cd3抗体及其药物用途 | |
| JP2015522525A5 (enExample) | ||
| JP2020507577A5 (enExample) | ||
| RU2019128204A (ru) | Белки, связывающиеся с psma, nkg2d и cd16 |